Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans

Microbiology

Volumn 145, Issue 10, 1999, Pages 2701-2713

  Marichal, Patrick ^a   Koymans, Luc ^a   Willemsens, Staf ^a   Bellens, Danny ^a   Verhasselt, Peter ^a   Luyten, Walter ^a   Borgers, Marcel ^b   Ramaekers, Frans C S ^b   Odds, Frank C ^a   Bossche, Hugo Vanden ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b NONE

Author keywords

Erg11p; Fluconazole; Itraconazole; Modelling; Resistance

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; PYRROLE; STEROL;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CANDIDA ALBICANS; FUNGUS MUTATION; MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEROL SYNTHESIS;

CANDIDA ALBICANS;

EID: 0032826408     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/00221287-145-10-2701     Document Type: Article

References (57)

1. Aoyama, Y., Horiuchi, T., Gotoh, O., Noshiro, M. & Yoshida, Y. (1998). CYP51-like gene of Mycobacterium tuberculosis actually encodes a P450 similar to eukaryotic CYP51. J Biochem 124, 694-696.
2. Bard, M., Lees, N. D., Turi, T., Craft, D., Cofrin, L., Barbuch, R., Koegel, C. & Loper, J. C. (1993). Sterol synthesis and viability of ERG11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28, 963-967.
3. Bellamine, A., Mangla, A. T., Nes, D. & Waterman, M. R. (1998). Is the Mycobacterium tuberculosis CYP51-like P450 a 14α-demethylase? In Program and Abstracts of the Fourth International Symposium on P450 Biodiversity and Biotechnology, Strasbourg, France. IC-11.
4. Bodey, G. P. (1997). Resistance to antimicrobial agents revisited. Curr Opin Infect Dis 10, 419-421.
5. Boscott, P. E. & Grant G. H. (1994). Modeling cytochrome P450 14α-demethylase (Candida albicans) from P450cam. J Mol Graph 12, 185-192.
6. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
7. Cartledge, J. D., Midgley, J. & Gazzard, B. G. (1997). Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS 11, 1839-1844.
8. De Muri, G. P. & Hostetter, M. K. (1995). Resistance to antifungal agents. Pediatr Clin N Am 42, 665-685.
9. Denning, D. W., Baily, G. G. & Hood, S. V. (1997). Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 16, 261-280.
10. Doignon, F., Aigle, M. & Ribereau-Gayon, P. (1993). Resistance to imidazoles and triazoles in Saccharomyces cerevisiae as a new dominant marker. Plasmid 30, 224-233.
11. Dupont, B. (1995). Azole antifungal agents : emerging and inherent resistance. Curr Opin Infect Dis 8, 424-427.
12. Frosco, M. & Barrett, J. F. (1998). Importance of antifungal drug-resistance: clinical significance and need for novel therapy. Exp Opin Invest Drugs 7, 175-198.
13. Hartman, P. G. & Sanglard, D. (1997). Inhibitors of ergosterol as antifungal agents. Curr Pharm Des 3, 177-208.
14. Hitchcock, C. A., Russell, N. J. & Barren-Bee, K. J. (1987). Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit Rev Microbiol 15, 111-115.
15. SG1: complete primary structure deduced from cloned DNAs. Biochem Biophys Res Commun 155, 317-323.
16. Johnson, E. M. & Warnock, D. W. (1995). Azole drug resistance in yeast. J Antimicrob Chemother 36, 751-755.
17. Joseph-Horn, T. & Hollomon, D.W. (1997). Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett 149, 141-149.
18. Kallakuri, S., Manavathu, E. K., Arganoza, M. T., Vazquez, J. A. & Sobel, J. D. (1996). Molecular characterization of the gene encoding cytochrome P450-dependent lanosterol 14α-demethylase from a fluconazole-resistant clinical isolate of Candida albicans. In Program and Abstracts of the 96th American Society for Microbiology General Meeting, New Orleans, Louisiana, 1996, Abstract F-63,p. 84. Washington, DC: American Society for Microbiology.
19. Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Schumacher, H. U. & Einsele, H. (1997). Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta 5,6-desaturation. FEBS Lett 400, 80-82.
20. Kolaczkowski, M. & Goffeau, A. (1997). Active efflux by multidrug transporters as one of the strategies to evade chemotherapy and novel practical implications of yeast pleiotropic drug resistance. Pharmacol Ther 76, 219-242.
21. Lai, M. H. & Kirsch, D. R. (1989). Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14α demethylase) from Candida albicans. Nucleic Acids Res 17, 804.
22. Lamb, D. C., Kelly, D. E., Schunck, W.-H., Shyadehi, A. Z., Akhtar, M., Lowe, D., Baldwin, B. C. & Kelly, S. L. (1997). The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 272, 5682-5688.
23. Löffler, J., Kelly, S. L., Hebart, H., Schumacher, U., Lass-Flörl, C. & Einsele, H. (1997). Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151, 263-268.
24. Manavathu, E. K., Kallakuri, S., Arganoza, M. T., Pierson, C. & Vazquez, J. A. (1996). Amino acid variations of cytochrome P450-dependent lanosterol 14α-demethylase (P450LDM) from a fluconazole-resistant clinical isolate of Candida albicans. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996, Abstract C68, p. 46. Washington, DC: American Society for Microbiology.
25. Marichal, P. & Vanden Bossche, H. (1995). Mechanisms of resistance to azole antifungals. Acta Biochim Pol 42, 509-516.
26. Marichal, P., Gorrens, J., Coene, M.-C., Le Jeune, L. & Vanden Bossche, H. (1995). Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 38, 111-117.
27. Marichal, P., Vanden Bossche, H., Odds, F. C. Nobels, G., Warnock, D. W., Timmerman, V., Van Broeckhoven, C., Fay, S. & Mose-Larsen, P. (1997). Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 41, 2229-2237.
28. Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A. & White, T. C. (1998). Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42, 2584-2589.
29. National Committee for Clinical Laboratory Standards (1995). Reference method for broth dilution susceptibility testing of yeasts. Tentative standard M27-A. Villanova, PA: National Committee for Clinical Laboratory Standards.
30. Odds, F. C. (1992). Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob Agents Chemother 36, 1727-1737.
31. Odds, F. C. (1998). Should resistance to azole antifungals in vitro be interpreted as predicating clinical non-response? Drug Res Updates 1, 11-15.
32. Odds, F. C., Vranckx, L. & Woestenborghs, F. (1995). Antifungal susceptibility testing of yeasts: Evaluation of technical variables for test automation. Antimicrob Agents Chemother 39, 2051-2060.
33. Okonogi, K., Asia, K., Tsuchimori, N., Perfect, J. R., Gotoh, O. & Yoshida, Y. (1998). A novel mechanism for emerging azole-resistant Candida albicans in AIDS patients. In Program and Abstracts of the Fourth International Symposium on P450 Biodiversity and Biotechnology, Strasbourg, France.
34. Orozco, A. S., Higginbotham, L. M., Hitchcock, C. A., Parkinson, T., Falconer, D., Ibrahim, A. S., Ghannoum, M. A. & Filler, S. G. (1998). Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 42, 2645-2649.
35. Pearce, M. A. & Howell, S. A. (1991). Restriction fragment length polymorphism analysis of azole-resistant and azole-susceptible Candida albicans strains. J Clin Microbiol 29, 1364-1367.
36. Rex, J. H., Rinaldi, M. G. & Pfaller, M. A. (1995). Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39, 1-8.
37. Rodriguez, R., Low, C., Bottema, C. & Parks, L. (1985). Multiple functions for sterols in Saccharomyces cerevisiae. Biochim Biophys Acta 837, 336-343.
38. Ryder, N. S. & Favre, B. (1997). Resistance to azoles in Candida albicans caused by mutations in the lanosterol 14α-demethylase gene. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997, Abstract C-13, p. 48. Washington, DC: American Society for Microbiology.
39. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M. & Bille, J. (1995). Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39, 2378-2386.
40. Sanglard, D., Ischer, F., Calabrese, D., de Micheli, M. & Bille, J. (1998a). Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Res Updates 1, 255-265.
41. Sanglard, D., Ischer, F., Koymans, L. & Bille, J. (1998b). Amino acid substitutions in the cytochrome P450 lanosterol 14alpha-demethylase (CYP51) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents. Antimicrob Agents Chemother 42, 241-253.
42. Smith, K. J., Warnock, D. W., Kennedy, C. T. C., Johnson, E. M., Hopwood, V., Van Cutsem, J. & Vanden Bossche, H. (1986). Azole resistance in Candida albicans. J Med Vet Mycol 24, 133-144.
43. Supply, P., Wach, A., Thines-Sempoux, D. & Goffeau, A. (1993). Proliferation of intracellular structures upon overexpression of the PMA2 ATPase in Saccharomyces cerevisiae. J Biol Chem 268, 19744-19752.
44. Vanden Bossche, H. (1997). Mechanisms of antifungal resistance. Rev Iberoam Micol 14, 44-49.
45. Vanden Bossche, H. & Koymans, L. (1997). Cytochromes P450 in fungi. Mycoses 41, (suppl. 1) 32-38.
46. Vanden Bossche, H., Willemsens, G., Cools, W., Cornelissen, F., Lauwers, W. F. & Van Cutsem, J. M. (1980). In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 17, 922-928.
47. Vanden Bossche, H., Bellens, D., Cools, W. & 10 other authors (1986). Cytochrome P-450: target for itraconazole. Drug Dev Res 8, 287-298.
48. Vanden Bossche, H., Marichal, P., Gorrens, J., Bellens, D., Verhoeven, H., Coene, M.-C., Lauwers, W. & Janssen, P. W. J. (1987). Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells, Pestic Sci 21, 1-13.
49. Vanden Bossche, H., Marichal, P., Gorrens, J., Bellens, D., Moereels, H. & Janssen, P. A. J. (1990). Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans 18, 56-59.
50. Vanden Bossche, H., Marichal, P., Odds, F. C., Le Jeune, L. & Coene, M.-C. (1992). Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 36, 2602-2610.
51. Vanden Bossche, H., Marichal, P. & Odds, F. C. (1994). Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2, 393-400.
52. Vanden Bossche, H., Dromer, F., Improvisi. L., Lozano-Chiu, M., Rex, J. H. & Sanglard, D. (1998). Antifungal drug resistance in pathogenic fungi. Med Mycol 36, (suppl. 1) 119-128.
53. Vergeres, G., Yen, T. S., Aggeler, J., Lausier, J. & Waskell, L. (1993). A model system for studying membrane biogenesis. Overexpression of cytochrome b5 in yeast results in marked proliferation of the intracellular membrane. J Cell Sci 106, 249-259.
54. Watson, P. F., Rose, M. E., Ellis, S. W., England, H. & Kelly, S. L. (1989). Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 164, 1170-1175.
55. White, T. C. (1997). The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α-demethylase in Candida albicans. Antimicrob Agents Chemother 41, 1488-1494.
56. White, T. C., Bowden, R. A. & Marr, K. A. (1998). Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11, 382-402.
57. Yoshida, Y. (1988). Cytochrome P450 of fungi, primary target for azole antifungal agents. Curr Top Med Mycol 2, 388-418.